Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...

Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...

Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

A large trial showed that semaglutide, sold as Ozempic for diabetes and as Wegovy for obesity, was better than any current ...

A blockbuster weight-loss drug sharply reduces pain from obesity-related arthritis in the knees and improves people’s ability ...